Krishna Institute of Medical Sciences will convene its 24th Annual General Meeting (AGM) on Thursday, August 27, 2026, at 4:00 PM IST via Video Conferencing/Other Audio Visual Means (VC/OAVM). The meeting aims to adopt the audited financial statements for FY26, re-appoint a retiring director, and seek shareholder approval for significant financial powers, including loan and guarantee limits up to ₹650 crore.

The notice, issued pursuant to Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines both ordinary and special business items. The ordinary business includes the consideration of standalone and consolidated financial statements for the year ended March 31, 2026, along with the reports of the Board of Directors and Auditors. Additionally, shareholders will vote on the re-appointment of Ms. Dandamudi Anitha (DIN: 00025480) as a Director, who retires by rotation.

Key Resolutions for Approval

The AGM agenda features three critical resolutions requiring shareholder consent:

Under Item 3, the Board seeks to ratify the remuneration of ₹6.00 Lakhs, excluding applicable taxes, payable to M/s. Sagar & Associates for conducting the cost audit for FY27. This appointment was recommended by the Audit Committee.

Financial Powers and Compliance

Items 4 and 5 involve special resolutions to expand the company’s financial flexibility. Under Section 185 of the Companies Act, 2013, the Board seeks approval to provide loans, guarantees, or securities to subsidiaries, associates, or joint ventures where directors have an interest, up to ₹650 crore over and above Section 186 limits. Similarly, under Section 186, the Board seeks approval for loans, guarantees, or investments in other bodies corporate up to ₹650 crore over the statutory limit of 60% of paid-up capital, free reserves, and securities premium, or 100% of free reserves and securities premium, whichever is higher.

The explanatory statement clarifies that these funds are intended for principal business activities, working capital requirements, and capital expenditure for new projects within the KIMS group. The Audit Committee will monitor these transactions periodically to ensure compliance with arm’s length principles and regulatory requirements. No directors or key managerial personnel have a financial interest in these resolutions.

Voting and Participation Details

Shareholders holding shares as of the record date, August 20, 2026, are eligible to vote. Remote e-voting will be available from August 24, 2026, at 9:00 AM IST to August 26, 2026, at 5:00 PM IST, facilitated by MUFG Intime India Private Limited. Members who vote remotely may still attend the AGM via VC/OAVM but cannot vote again during the meeting. Physical attendance is dispensed with as per Ministry of Corporate Affairs circulars.

Krishna Institute of Medical Sciences will host analysts and institutional investors at Emkay Confluence 2026 on August 12, 2026, in Mumbai. The healthcare company announced the engagement schedule on August 4, 2026, providing stakeholders with an opportunity to interact with management regarding business operations and strategic direction. This group meeting format allows multiple investors to engage with company leadership simultaneously, ensuring broad dissemination of information.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Krishna Institute of Medical Sciences Limited submitted the intimation to both the Bombay Stock Exchange Ltd (BSE) and the National Stock Exchange (NSE). The company is listed under Scrip Code 543308 on BSE and Symbol KIMS on NSE, with ISIN INE967H01025.

Meeting Details

The event is scheduled as a group meeting, meaning it will not be a one-on-one session but rather a collective interaction with various market participants. The venue for Emkay Confluence 2026 is Mumbai, India.

The company noted that the schedule is subject to change due to exigencies, if any. Investors are advised to monitor official communications for any updates regarding timing or venue adjustments.

Compliance and Information Disclosure

Krishna Institute of Medical Sciences Limited explicitly stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the meeting. This assurance aligns with regulatory requirements designed to prevent insider trading and ensure fair access to material information for all market participants.

The disclosure was authorized by Nagajayanthi J.R., Company Secretary & Compliance Officer of Krishna Institute of Medical Sciences Limited. The notice was digitally signed on August 4, 2026, at 16:41:50 +05'30'.

What This Means for Investors

Analyst meetings serve as critical touchpoints for institutional investors and equity research analysts to gauge management sentiment and operational health. For Krishna Institute of Medical Sciences Limited, participating in Emkay Confluence 2026 signals its commitment to maintaining transparent communication with the investment community. While no specific financial results or strategic announcements were previewed in the filing, such events often provide context for recent performance trends or future growth initiatives within the healthcare sector.